Morita Katsuya, Motoyama Naoyo, Kitayama Tomoya, Morioka Norimitsu, Kifune Koki, Dohi Toshihiro
Department of Pharmacology, Division of Integrated Medical Science, Hiroshima University Graduate School of Biomedical Sciences, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8553, Japan.
J Pharmacol Exp Ther. 2008 Aug;326(2):633-45. doi: 10.1124/jpet.108.136267. Epub 2008 Apr 30.
Neuropathic pain is refractory against conventional analgesics, and thus novel medicaments are desired for the treatment. Glycinergic neurons are localized in specific brain regions, including the spinal cord, where they play an important role in the regulation of pain signal transduction. Glycine transporter (GlyT)1, present in glial cells, and GlyT2, located in neurons, play roles in modulating glycinergic neurotransmission by clearing synaptically released glycine or supplying glycine to the neurons and thus could modify pain signal transmission in the spinal cord. In this study, we demonstrated that i.v. or intrathecal administration of GlyT1 inhibitors, cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl methyl)amino methylcarboxylic acid (ORG25935) or sarcosine, and GlyT2 inhibitors, 4-benzyloxy-3,5-dimethoxy-N-[1-(dimethylaminocyclopently)-methyl]benzamide (ORG25543) and (O-[(2-benzyloxyphenyl-3-fluorophenyl)methyl]-L-serine) (ALX1393), or knockdown of spinal GlyTs by small interfering RNA of GlyTs mRNA produced a profound antiallodynia effect in a partial peripheral nerve ligation model and other neuropathic pain models in mice. The antiallodynia effect is mediated through spinal glycine receptor alpha3. These results established GlyTs as the target molecules for the development of medicaments for neuropathic pain. However, these manipulations to stimulate glycinergic neuronal activity were without effect during the 4 days after nerve injury, whereas manipulations to inhibit glycinergic neuronal activity protected against the development of allodynia in this phase. The results implied that the timing of medication with their inhibitors should be considered, because glycinergic control of pain was reversed in the critical period of 3 to 4 days after surgery. This may also provide important information for understanding the underlying molecular mechanisms of the development of neuropathic pain.
神经性疼痛对传统镇痛药具有抗性,因此需要新型药物进行治疗。甘氨酸能神经元定位于特定脑区,包括脊髓,它们在疼痛信号转导的调节中发挥重要作用。存在于胶质细胞中的甘氨酸转运体(GlyT)1和位于神经元中的GlyT2,通过清除突触释放的甘氨酸或向神经元供应甘氨酸来调节甘氨酸能神经传递,从而可能改变脊髓中的疼痛信号传递。在本研究中,我们证明静脉注射或鞘内注射GlyT1抑制剂顺式-N-甲基-N-(6-甲氧基-1-苯基-1,2,3,4-四氢萘-2-基甲基)氨基甲基羧酸(ORG25935)或肌氨酸,以及GlyT2抑制剂4-苄氧基-3,5-二甲氧基-N-[1-(二甲基氨基环戊基)-甲基]苯甲酰胺(ORG25543)和(O-[(2-苄氧基苯基-3-氟苯基)甲基]-L-丝氨酸)(ALX1393),或通过GlyTs mRNA的小干扰RNA敲低脊髓中的GlyTs,在小鼠部分外周神经结扎模型和其他神经性疼痛模型中产生了显著的抗痛觉过敏作用。抗痛觉过敏作用是通过脊髓甘氨酸受体α3介导的。这些结果确立了GlyTs作为开发神经性疼痛药物的靶分子。然而,这些刺激甘氨酸能神经元活动的操作在神经损伤后的4天内没有效果,而抑制甘氨酸能神经元活动的操作在这个阶段可预防痛觉过敏的发生。结果表明,应考虑使用其抑制剂的用药时机,因为在术后3至4天的关键时期,甘氨酸能对疼痛的控制发生了逆转。这也可能为理解神经性疼痛发生的潜在分子机制提供重要信息。